ASIT Platform
Myasthenia Gravis
Key Facts
About Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileAbout Ahead Therapeutics
Ahead Therapeutics is a private, preclinical-stage biotech focused on a curative approach for autoimmune diseases via its proprietary nanotechnology platform. The company's core technology, ASIT (Antigen-Specific Immune Tolerance), uses biomimetic nanoparticles to deliver auto-antigens to specific immune cells, aiming to re-educate the immune system without suppressing it systemically. Its pipeline includes multiple high-need autoimmune indications, and it has gained early validation through a significant grant and positive regulatory feedback from the EMA.
View full company profileTherapeutic Areas
Other Myasthenia Gravis Drugs
| Drug | Company | Phase |
|---|---|---|
| Batoclimab (HBM9161) | Harbour BioMed | Phase 3 |
| Nipocalimab | johnson-and-johnson-innovative-medicine | Phase 3 |
| Myasthenia Gravis Live CBA Panel | Neurocode | Commercial |
| KYV-101 (mivocabtagene autoleucel) | Kyverna Therapeutics | Phase 2 |